Figure 1.

Trial design. (A) Schematic study design. (B) Consolidated Standards of Reporting Trials (CONSORT) flow diagram for the trial. ^*Viral rebound during MAP was defined as pVL >20 copies/ml and ^#criteria for ART resumption included pVL over 2,000 copies/ml in two consecutive determinations, CD4⁺ cell counts decrease over 50% and/or below 500 cells/mm³ and/or development of clinical symptoms suggestive of an acute retroviral syndrome. MVA, MVA.HIVconsv vaccine; RMD, romidepsin; MAP, monitored antiretroviral pause; ART, antiretroviral therapy; pVL, plasma HIV-1 viral load.